DELSOL Avocats is proud to be ranked in 10 Legal 500 EMEA 2024 categories : Construction – Tier 3 Data privacy and data protection – Tier 3 Dispute resolution : Commercial litigation – Tier 4 Dispute resolution : White-collar crime – Tier 4 Employment –
ReadCamille NICOLAÏ
Gaëlle MERLIER
Armelle DUNAND
Jeanne BOSSI MALAFOSSE
Victoire STÖRKSEN
Valentin MOTTELAY
Aura BRAUN
The “Life sciences” department works with companies involved in health and medical technologies, as well as their partners, at all steps in the lives of their products, as part of their development, pre-clinical or clinical assessment, valuation of innovations, marketing, reimbursement or distribution.
The department’s team also advises health establishments of any form, as well as companies and organisations in this sector, relative to their relations with health professionals. For certain customers, it provides outsourced management of the procedures relative to the implementation of these contractual relations.
The lawyers in the “Life sciences” department are distinguished by the particular assistance that they provide to their clients during inspections performed by health authorities, and as part of the defence of their interests in the event of administrative or judicial disputes.
Moreover, faced with the development of digital technology that’s now leading to a true “datafication” of our societies, the definition of a strategy for optimal data management and exploitation is becoming a major concern for all actors in the health sector.
Knowledge and familiarity with the legal and functional framework by actors and the role that they play in health information systems regardless of the objective – management of medical files, research files, medical-social monitoring, hosting, etc. – are essential for everyone involved in today’s health sector.
The “Life sciences” department works with you on the following subjects :
- assistance with the regulatory framework for projects involving health information systems (tele-medicine, health cooperation consortia, territorial hospital groups, etc.),
- assistance with understanding the new rules for exchanges and sharing of health data within the health sector and within the medical-social sector, drafting of hosting contracts for health data and coordination of the various required authorisations,
- consultations on the conditions for accessing health data (including Big data issues), etc.
The department’s members provide extensive inter- and intra-company training in the areas of clinical research, health data, administrative inspections, the usage of biological samples, health products, the valuation of innovations, regulatory compliance, etc.
Given the cross-disciplinary nature of many files entrusted to the “Life sciences” department, and in order to respond to the range and complexity of issues arising for the actors in this sector, these files are handled in close collaboration with the firm’s other departments, primarily the “Personal data”, “Corporate law – Mergers-acquisitions”, “Non-profit organisations”, “Public law” and “Disputes” departments.
The team works in French or English.
Rankings of the department
- LEGAL 500 EMEA 2024
- in Tier 2 in Health care & life sciences
- PALMARES DU DROIT 2024
- (Paris) – Life sciences : Bronze Trophy
- DECIDEURS 2024
- E-health : Unbeatable
- Advice to health care institutions - hospital cooperation : Excellent
- 2024-03-27
- Mathieu LE TACON, Jeanne BOSSI MALAFOSSE, Gaëlle MERLIER
- Legal news
- 2024-03-26
- Legal news
DELSOL Avocats has once again been distinguished at the Palmarès du Droit organised in Paris by Le Monde du Droit. The expertise of our teams was rewarded in the following categories : Tax Litigation : Golden trophy Wealth law : Golden trophy Non-profit organisations : Golden trophy Mergers - Acquisitions : transactions < €50M : Silver...
Read- 2024-02-29
- Gaëlle MERLIER
- Legal news
What is a biosimilar product ? A biosimilar is a biological medicine (i.e., a medicine whose active substance is made by a living organism) highly similar to another already approved biological medicine (the « reference medicine »EMA, [1]) . According to the European Medicines Agency (« EMA »), biosimilar medicines have become major therapeutic...
Read- 2023-04-12
- Mathieu LE TACON, Jeanne BOSSI MALAFOSSE, Gaëlle MERLIER
- Legal news
DELSOL Avocats is proud to be ranked in 9 Legal 500 EMEA 2023 categories : Construction – Tier 3 Data privacy and data protection – Tier 3 Dispute resolution : White-collar crime – Tier 4 Employment – Tier 4 Industry focus : Healthcare and life sciences – Tier 3 Mergers & Acquisitions – Tier 5 Private equity : venture/growth...
Read